SABS
SAB Biotherapeutics Inc

1,666
Mkt Cap
$171.1M
Volume
150,076.00
52W High
$6.60
52W Low
$1.00
PE Ratio
-1.16
SABS Fundamentals
Price
$3.81
Prev Close
$3.59
Open
$3.54
50D MA
$3.17
Beta
0.84
Avg. Volume
210,221.68
EPS (Annual)
-$3.68
P/B
1.03
Rev/Employee
$20,990.63
Loading...
Loading...
News
all
press releases
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company...
MarketBeat·9d ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen raised SAB Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·20d ago
News Placeholder
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago
News Placeholder
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
chainwire·7mo ago

Latest SABS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.